Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder

Loading news article.

Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder | WAPE

Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder

Article summary

Related companies

Comments —